Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2014

View Archived Issues

Dong Wha licenses natural extracts for IBD from Kyung Hee University

Sanofi reflects on accomplishments of second quarter 2014

Dignity Sciences completes phase I trial of oral DS-107G

Lightlake Therapeutics receives funding for development of intranasal naloxone

Sirona Biochem synthesizes first compound in joint venture with Bloom Burton

Targazyme awarded grant to study treatment of retinopathy using autologous stem cells

GlaxoSmithKline discloses new FAS inhibitors for cancer

Chinese researchers divulge novel coagulation factor Xa inhibitors

Sichuan University divulges novel AChE inhibitors

Sanofi synthesizes novel SEH inhibitors

Development of a novel, potent enzyme inhibitor for the treatment of type 2 diabetes

Scientists at Roche disclose novel OT-R agonists for CNS disorders

GSK and Genmab report interim data for phase III study of ofatumumab in relapsed CLL

Alexza Pharmaceuticals provides pipeline update

TNT-003 inhibits anti-HLA antibody-induced complement deposition in vitro

Genzyme receives label expansion for Lumizyme in the U.S.

Preclinical murine skin allograft model results presented for CD28-specific domain antibody

Shionogi offers overview of first quarter of fiscal 2014

Amarantus reports data for LymPro Test and licenses property from University of Leipzig

Cysteamine bitartrate receives European orphan drug status for Huntington's disease

Medivir licenses RSV drug program from Boehringer Ingelheim

Roche to acquire Santaris Pharma

Laninamivir octanoate misses primary endpoint in phase II influenza trial

FDA grants orphan drug designation to Genoa's inhaled pirfenidone for IPF

U.S. and E.U. orphan drug designations for AbbVie's ABT-414 for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...